NCT04227509

Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

A Randomized Phase II Study of CONsolidation PEmbrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of pembrolizumab until disease progression or recurrence

Detailed description

Phase II multi-center, randomized controlled trial of consolidation pembrolizumab after chemoradiotherapy in locally advanced nasopharyngeal carcinoma

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
DRUG	Placebo	normal saline will be administered as a 30 minute IV infusion every 3 weeks.

Timeline

• Start date: 2020-06-04
• Primary completion: 2024-08-21
• Completion: 2024-08-21
• First posted: 2020-01-13
• Last updated: 2025-12-31

Locations

1 site across 1 country: South Korea